4.6 Review

Epigenetics of Thymic Epithelial Tumors

期刊

CANCERS
卷 15, 期 2, 页码 -

出版社

MDPI
DOI: 10.3390/cancers15020360

关键词

thymic epithelial tumors; thymoma; thymic carcinoma; DNA methylation; histone tail modifications; ncRNAs; microRNAs; thymoma-associated myasthenia gravis (TAMG); epigenetics; biomarker

类别

向作者/读者索取更多资源

Thymic epithelial tumors (TETs) arise from the epithelial cells of the thymus and account for 1% of all adult malignancies, despite being the most common lesions of the anterior mediastinum. TETs can be classified into different subtypes, including thymomas, thymic carcinomas, and neuroendocrine forms. The challenge lies in the diagnosis and characterization of TETs due to the lack of symptoms and the presence of paraneoplastic disorders. Epigenetic profiling has been explored as a potential tool for tumor characterization and clinical outcomes prediction.
Simple Summary Thymic epithelial tumors (TETs) are rare malignancies that arise from the epithelial cells of the thymus. In most cases, TETs are characterized by a good prognosis, and their aggressiveness reflects the histopathological subtypes defined in the guidelines of the World Health Organization. Over the years, the challenge has been to characterize TETs at both genetic and epigenetic levels, revealing a deep deregulation of key cellular pathways linked to cancer onset and development or autoimmunity. The present work collects the main research concerning the epigenetic deregulation of TETs, with a special focus on DNA methylation, histone tail modifications, and non-coding RNAs dysregulation potentially useful for clinical practice. Thymic epithelial tumors (TETs) arise from the epithelial cells of the thymus and consist in the 1% of all adult malignancies, despite the fact that they are the most common lesions of the anterior mediastinum. TETs can be divided mainly into thymomas, thymic carcinomas, and the rarest ad aggressive neuroendocrine forms. Despite the surgical resection is quite resolving, the diagnosis of TETs is complicated by the absence of symptoms and the clinical presentation aggravated by several paraneoplastic disorders, including myasthenia gravis. Thus, the heterogeneity of TETs prompts the search for molecular biomarkers that could be helpful for tumor characterization and clinical outcomes prediction. With these aims, several researchers investigated the epigenetic profiles of TETs. In this manuscript, we narratively review the works investigating the deregulation of epigenetic mechanisms in TETs, highlighting the need for further studies combining genetic, epigenetic, and expression data to better characterize the different molecular subtypes and identify, for each of them, the most relevant epigenetic biomarkers of clinical utility.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.6
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据